Basilea announced a clinical trial supply collaboration with Roche to explore the combination of its in-licensed oncology drug candidate derazantinib with Roche’s PDL1 immune checkpoint inhibitor ("ICI") atezolizumab (Tecentriq) in urothelial cancer ("UC"), the most common type of bladder cancer and sixth largest cancer in the US. A Phase I/II biomarker-driven study is projected to start in mid-2019E. Derazantinib has already demonstrated activity as a single agent in shrinking tumours of patien ....
25 Jan 2019
Derazantinib to enter combo trial with Roche's Tecentriq
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Derazantinib to enter combo trial with Roche's Tecentriq
Basilea Pharmaceutica AG (0QNA:LON) | 4,620 0 0.0% | Mkt Cap: 605.3m
- Published:
25 Jan 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
5
Basilea announced a clinical trial supply collaboration with Roche to explore the combination of its in-licensed oncology drug candidate derazantinib with Roche’s PDL1 immune checkpoint inhibitor ("ICI") atezolizumab (Tecentriq) in urothelial cancer ("UC"), the most common type of bladder cancer and sixth largest cancer in the US. A Phase I/II biomarker-driven study is projected to start in mid-2019E. Derazantinib has already demonstrated activity as a single agent in shrinking tumours of patien ....